MindWalk Holdings (HYFT) EBITDA (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly EBITDA of -$2.3 billion for Q2 2026, down 95.61% year-over-year from -$53.0 billion in Q2 2025, and down 12999563.61% quarter-over-quarter from -$17912.6 in Q1 2026.
MindWalk Holdings (HYFT) EBITDA (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported EBITDA for 7 consecutive years, with -$2.3 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, EBITDA fell 95.61% year-over-year to -$2.3 billion; the TTM figure through Apr 2026 stood at -$2.3 billion (up 50.96% YoY), while the FY2026 annual figure was -$2.3 billion, up 42.98% from the prior year.
- EBITDA declined to -$2.3 billion in Q2 2026 per HYFT's latest filing, from -$17912.6 in the prior quarter.
- Across five years, EBITDA topped out at $16.6 million in Q2 2023 and bottomed at -$3.6 billion in Q3 2024.
- Historically, EBITDA has averaged -$394.0 million across 5 years, with a median of -$1.0 million in 2025.
- Annual changes were most pronounced in 2023 — EBITDA surged 590.74% — and 2024, when it slumped 117339930.13%.
- MindWalk Holdings' EBITDA stood at -$5.89 in 2022, then slumped by 35218.16% to -$2080.5 in 2023, then plunged by 142593.62% to -$3.0 million in 2024, then surged by 32.62% to -$2.0 million in 2025, then sank by 116303.6% to -$2.3 billion in 2026.
- Business Quant data shows HYFT's EBITDA at -$2.3 billion in Q2 2026, -$17912.6 in Q1 2026, and -$2.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2.33 Bn |
| Jan 31, 2026 | -17,912.64 |
| Oct 31, 2025 | -2.00 Mn |
| Jul 31, 2025 | 0.00 |
| Apr 30, 2025 | -1.19 Bn |
| Jan 31, 2025 | -17.51 |
| Oct 31, 2024 | -2.97 Mn |
| Jul 31, 2024 | -3.56 Bn |
| Apr 30, 2024 | -16.47 Mn |
| Jan 31, 2024 | -2.47 Mn |
| Oct 31, 2023 | -2,080.47 |
| Jul 31, 2023 | -3,033.53 |
| Apr 30, 2023 | 16.61 Mn |
| Jan 31, 2023 | -3.40 Mn |
| Oct 31, 2022 | -5.89 |
| Jul 31, 2022 | -7,831.25 |
| Apr 30, 2022 | -3.38 Mn |
| Jan 31, 2022 | -3,402.88 |
| Oct 31, 2021 | -3,729.01 |
| Jul 31, 2021 | -2,821.27 |